Naturally Acquired Immune Responses to P. vivax Merozoite Surface Protein 3α and Merozoite Surface Protein 9 Are Associated with Reduced Risk of P. vivax Malaria in Young Papua New Guinean Children

PLoS Neglected Tropical Diseases

Volumn 7, Issue 11, 2013, Pages

  Stanisic, Danielle I ^a,b   Javati, Sarah ^b   Kiniboro, Benson ^b   Lin, Enmoore ^b   Jiang, Jianlin ^c   Singh, Balwan ^c   Meyer, Esmeralda V S ^c   Siba, Peter ^b   Koepfli, Cristian ^a,d,e   Felger, Ingrid ^d,e   Galinski, Mary R ^c,f   Mueller, Ivo ^a,b,g  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b PAPUA NEW GUINEA INSTITUTE OF MEDICAL RESEARCH   (Papua New Guinea)

^c EMORY UNIVERSITY   (United States)

^d SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; HEMOGLOBIN; IMMUNOGLOBULIN G; MEROZOITE SURFACE PROTEIN 3ALPHA; MEROZOITE SURFACE PROTEIN 9; MICROORGANISM PROTEIN; UNCLASSIFIED DRUG; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ARTICLE; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; IMMUNE RESPONSE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PARASITEMIA; PLASMODIUM VIVAX MALARIA; PRESCHOOL CHILD; PREVALENCE; IMMUNOLOGY; INFANT; MALARIA, VIVAX; PAPUA NEW GUINEA; PATHOGENICITY; PLASMODIUM VIVAX;

ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALARIA, VIVAX; MALE; PAPUA NEW GUINEA; PLASMODIUM VIVAX;

EID: 84888238132     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002498     Document Type: Article

References (50)

1. Galinski MR, Barnwell JW, (2008) Plasmodium vivax: who cares? Malaria Journal 7: S9.
2. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, et al. (2009) Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis 9: 555-566.
3. Manning L, Laman M, Law I, Bona C, Aipit S, et al. (2012) Features and prognosis of severe malaria caused by Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New Guinean children. PLoS One 6: e29203.
4. Bassat Q, Alonso PL, (2011) Defying malaria: Fathoming severe Plasmodium vivax disease. Nat Med 17: 48-49.
5. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, et al. (2008) Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS medicine 5: e128.
6. Barcus MJ, Basri H, Picarima H, Manyakori C, Sekartuti, et al. (2007) Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg 77: 984-991.
7. Akinyi S, Hanssen E, Meyer EV, Jiang J, Korir CC, et al. (2012) A 95 kDa protein of Plasmodium vivax and P. cynomolgi visualized by three-dimensional tomography in the caveola-vesicle complexes (Schuffner's dots) of infected erythrocytes is a member of the PHIST family. Mol Microbiol 84: 816-831.
8. Krotoski WA, Collins WE, Bray RS, Garnham PC, Cogswell FB, et al. (1982) Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am J Trop Med Hyg 31: 1291-1293.
9. Boyd M, Kitchen S, (1937) On the infectiousness of patients infected with Plasmodium vivax and Plasmodium falciparum. Am J Trop Med Hyg s1-17: 253-262.
10. Kitchen S, (1938) The infection of reticulocytes by Plasmodium vivax. Am J Trop Med Hyg s1-18: 347-359.
11. Yazdani SS, Shakri AR, Mukherjee P, Baniwal SK, Chitnis CE, (2004) Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Vaccine 22: 3727-3737.
12. Oliveira-Ferreira J, Vargas-Serrato E, Barnwell JW, Moreno A, Galinski MR, (2004) Immunogenicity of Plasmodium vivax merozoite surface protein-9 recombinant proteins expressed in E. coli. Vaccine 22: 2023-2030.
13. Galinski MR, Corredor-Medina C, Povoa M, Crosby J, Ingravallo P, et al. (1999) Plasmodium vivax merozoite surface protein-3 contains coiled-coil motifs in an alanine-rich central domain. Mol Biochem Parasitol 101: 131-147.
14. Galinski MR, Ingravallo P, Corredor-Medina C, Al-Khedery B, Povoa M, et al. (2001) Plasmodium vivax merozoite surface proteins-3beta and-3gamma share structural similarities with P. vivax merozoite surface protein-3alpha and define a new gene family. Mol Biochem Parasitol 115: 41-53.
15. King C, Michon P, Shakri A, Marcotty A, Stanisic D, et al. (2008) Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection. Proc Natl Scad Sci USA 105: 8363-8368.
16. Ntumngia FB, Schloegel J, Barnes SJ, McHenry AM, Singh S, et al. (2012) Conserved and Variant Epitopes of Plasmodium vivax Duffy Binding Protein as Targets of Inhibitory Monoclonal Antibodies. Infect Immun 80: 1203-1208.
17. Ménard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray L, et al. (2010) Plasmodium vivax Clinical Malaria is Commonly Observed in Duffy-negative Malagasy People. Proc Natl Acad Sci USA 106: 5967-5971.
18. Jiang J, Barnwell JW, Meyer EV, Galinski M, (2013) Plasmodium vivax Merozoite Surface Protein-3 (PvMSP3): Expression of an 11 member multigene family in blood-stage parasites. Plos One Accepted.
19. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, et al. (1994) Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84: 1594-1602.
20. Sirima SB, Cousens S, Druilhe P, (2011) Protection against malaria by MSP3 candidate vaccine. N Engl J Med 365: 1062-1064.
21. Bitencourt AR, Vicentin EC, Jimenez MC, Ricci R, Leite JA, et al. (2013) Antigenicity and immunogenicity of Plasmodium vivax merozoite surface protein-3. PLoS One 8: e56061.
22. Bruce MC, Galinski MR, Barnwell JW, Snounou G, Day KP, (1999) Polymorphism at the merozoite surface protein-3alpha locus of Plasmodium vivax: global and local diversity. Am J Trop Med Hyg 61: 518-525.
23. Mueller I, Kaiok J, Reeder JC, Cortes A, (2002) The population structure of Plasmodium falciparum and Plasmodium vivax during an epidemic of malaria in the Eastern Highlands of Papua New Guinea. Am J Trop Med Hyg 67: 459-464.
24. Ord R, Polley S, Tami A, Sutherland CJ, (2005) High sequence diversity and evidence of balancing selection in the PvMSP3alpha gene of Plasmodium vivax in the Venezuelan Amazon. Mol Biochem Parasitol 144: 86-93.
25. Cui L, Mascorro CN, Fan Q, Rzomp KA, Khuntirat B, et al. (2003) Genetic diversity and multiple infections of Plasmodium vivax malaria in Western Thailand. Am J Trop Med Hyg 68: 613-619.
26. Rayner JC, Corredor V, Feldman D, Ingravallo P, Iderabdullah F, et al. (2002) Extensive polymorphism in the Plasmodium vivax merozoite surface coat protein MSP-3alpha is limited to specific domains. Parasitology 125: 393-405.
27. Lima-Junior JC, Jiang J, Rodrigues-da-Silva RN, Banic DM, Tran TM, et al. (2011) B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax merozoite surface protein-3alpha (PvMSP-3alpha) in malaria exposed individuals from Brazilian Amazon. Vaccine 29: 1801-1811.
28. Lima-Junior JC, Rodrigues-da-Silva RN, Banic DM, Jiang J, Singh B, et al. (2012) Influence of HLA-DRB1 and HLA-DQB1 Alleles on IgG Antibody Response to the P. vivax MSP-1, MSP-3alpha and MSP-9 in Individuals from Brazilian Endemic Area. Plos One 7: e36419.
29. Vargas-Serrato E, Barnwell JW, Ingravallo P, Perler FB, Galinski MR, (2002) Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P. falciparum. Mol Biochem Parasitol 120: 41-52.
30. Barnwell JW, Galinski MR, DeSimone SG, Perler F, Ingravallo P, (1999) Plasmodium vivax, P. cynomolgi, and P. knowlesi: identification of homologue proteins associated with the surface of merozoites. Exp Parasitol 91: 238-249.
31. Lima-Junior JC, Tran TM, Meyer EV, Singh B, De-Simone SG, et al. (2008) Naturally acquired humoral and cellular immune responses to Plasmodium vivax merozoite surface protein 9 in Northwestern Amazon individuals. Vaccine 26: 6645-6654.
32. Lima-Junior JC, Banic DM, Tran TM, Meyer VS, De-Simone SG, et al. (2010) Promiscuous T-cell epitopes of Plasmodium merozoite surface protein 9 (PvMSP9) induces IFN-gamma and IL-4 responses in individuals naturally exposed to malaria in the Brazilian Amazon. Vaccine 28: 3185-3191.
33. Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, et al. (2010) Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. Plos One 5: e9047.
34. Mueller I, Genton B, Rare L, Kiniboro B, Kastens W, et al. (2009) Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection. Malaria journal 8: 158.
35. McNamara D, Thomson J, Kasehagen L, Zimmerman P, (2004) Development of multiplex PCR-ligase detection reaction assay for diagnosis of infection by the four parasite species causing malaria in humans. J Clin Micro 42: 2403-2410.
36. Stanisic D, Richards J, McCallum F, Michon P, King C, et al. (2009) IgG subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun 77: 1165-1174.
37. Koepfli C, Benton KL, Lin E, Kiniboro B, Zimmerman PA, et al. (submitted) A high force of Plasmodium vivax blood-stage infection drives the rapid acquisition of immunity in Papua New Guinean children. PLoS Neglected Tropical Diseases.
38. Koepfli C, Ross A, Kiniboro B, Smith TA, Zimmerman PA, et al. (2011) Multiplicity and Diversity of Plasmodium vivax Infections in a Highly Endemic Region in Papua New Guinea. PLoS neglected tropical diseases 5: e1424.
39. Mueller I, Schoepflin S, Smith TA, Benton KL, Bretscher MT, et al. (2012) Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A 109: 10030-10035.
40. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P, (1990) Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172: 1633-1641.
41. Egan A, Burghaus P, Druilhe P, Holder A, Riley E, (1999) Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Para Immunol 21: 133-139.
42. Khusmith S, Druilhe P, (1983) Antibody-dependent ingestion of P. falciparum merozoites by human blood monocytes. Para Immunol 5: 357-368.
43. Khusmith S, Druilhe P, (1983) Cooperation between antibodies and monocytes that inhibit in vitro proliferation of Plasmodium falciparum. Infect Immun 41: 219-223.
44. Blackman M, Heidrich H-G, Donachie S, McBride J, Holder A, (1990) A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. Journal of Experimental Medicine 172: 379-382.
45. Grimberg BT, Udomsangpetch R, Xainli J, McHenry A, Panichakul T, et al. (2007) Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med 4: e337.
46. Cole-Tobian JL, Cortes A, Baisor M, Kastens W, Xainli J, et al. (2002) Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Dis 186: 531-539.
47. Levitus G, Mertens F, Speranca MA, Camargo LM, Ferreira MU, et al. (1994) Characterization of naturally acquired human IgG responses against the N-terminal region of the merozoite surface protein 1 of Plasmodium vivax. Am J Trop Med Hyg 51: 68-76.
48. Seth RK, Bhat AA, Rao DN, Biswas S, (2010) Acquired immune response to defined Plasmodium vivax antigens in individuals residing in northern India. Microbes Infect 12: 199-206.
49. Nogueira P, Alves F, Fernandez-Becerra C, Pein O, Santos N, et al. (2006) A reduced risk of infection with Plasmodium vivax and clinical protection against malaria are associated with antibodies against the N terminus but not the C terminus of merozoite surface protein 1. Infect Immun 74: 2726-2733.
50. Cole-Tobian JL, Michon P, Biasor M, Richards JS, Beeson JG, et al. (2009) Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children. Infect Immun 77: 4009-4017.